# scientific reports

# OPEN

Check for updates

# The benefit of planned dialysis to early survival on hemodialysis versus peritoneal dialysis: a nationwide prospective multicenter study in Korea

Jeong-Hoon Lim<sup>1,2,8</sup>, Ji Hye Kim<sup>1,2,8</sup>, Yena Jeon<sup>2,3</sup>, Yon Su Kim<sup>2,4</sup>, Shin-Wook Kang<sup>2,5</sup>, Chul Woo Yang<sup>2,6</sup>, Nam-Ho Kim<sup>2,7</sup>, Hee-Yeon Jung<sup>1,2</sup>, Ji-Young Choi<sup>1,2</sup>, Sun-Hee Park<sup>1,2</sup>, Chan-Duck Kim<sup>1,2</sup>, Yong-Lim Kim<sup>1,2</sup> & Jang-Hee Cho<sup>1,2</sup>

Optimal preparation is recommended for patients with advanced chronic kidney disease to minimize complications during dialysis initiation. This study evaluated the effects of planned dialysis initiation on survival in patients undergoing incident hemodialysis and peritoneal dialysis. Patients newly diagnosed with end-stage kidney disease who started dialysis were enrolled in a multicenter prospective cohort study in Korea. Planned dialysis was defined as dialysis therapy initiated with permanent access and maintenance of the initial dialysis modality. A total of 2892 patients were followed up for a mean duration of 71.9 ± 36.7 months and 1280 (44.3%) patients initiated planned dialysis. The planned dialysis group showed lower mortality than the unplanned dialysis group during the 1st and 2nd years after dialysis initiation (1st year: adjusted hazard ratio [aHR] 0.51; 95% confidence interval [CI] 0.37–0.72; P < 0.001; 2nd year: aHR 0.71; 95% CI 0.52–0.98, P = 0.037). However, 2 years after dialysis initiation, mortality did not differ between the groups. Planned dialysis showed a better early survival rate in hemodialysis patients, but not in peritoneal dialysis patients. Particularly, infection-related mortality was reduced only in patients undergoing hemodialysis with planned dialysis initiation. Planned dialysis has survival benefits over unplanned dialysis in the first 2 years after dialysis initiation, especially in patients undergoing hemodialysis. It improved infectionrelated mortality during the early dialysis period.

The global prevalence of end-stage kidney disease (ESKD) is steadily increasing<sup>1</sup>. Although the mortality rate of patients with ESKD has improved, ESKD remains one of the conditions that greatly increases the risk of death<sup>2</sup>. Particularly, the highest mortality rate has been reported during the early period after dialysis initiation<sup>3-6</sup>. Several risk factors, such as old age, anemia, comorbid cardiovascular disease, and malnutrition<sup>7-11</sup>, are associated with greater mortality risk during the early dialysis period. Early referral to nephrologists for patients with chronic kidney disease (CKD) has been reported as a modifiable factor in reducing early mortality after dialysis initiation<sup>12-14</sup>.

Early referral identifies and corrects the reversible causes of CKD and delays the progression of renal insufficiency<sup>15-17</sup>. Additionally, patients with CKD who are referred early can receive specialized management in various areas, such as blood pressure, electrolyte levels, and cholesterol levels, resulting in reduced cardiovascular

<sup>1</sup>Division of Nephrology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, 130 Dongdeok-ro, Jung-gu, Daegu 41944, South Korea. <sup>2</sup>Clinical Research Center for End Stage Renal Disease, Daegu, South Korea. <sup>3</sup>Department of Statistics, Kyungpook National University, Daegu, South Korea. <sup>4</sup>Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea. <sup>5</sup>Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea. <sup>6</sup>Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, South Korea. <sup>7</sup>Department of Internal Medicine, Chonnam National University Medical School, Gwangju, South Korea. <sup>8</sup>These authors contributed equally: Jeong-Hoon Lim and Ji Hye Kim. <sup>Se</sup>email: ylkim@knu.ac.kr; jh-cho@ knu.ac.kr mortality<sup>18–20</sup>. However, Marron et al. reported that despite sufficient time, nearly half of the referred patients with CKD did not receive adequate education on renal replacement therapy options<sup>21</sup>. The lack of sufficient education hinders planned dialysis and increases patient complications and medical costs<sup>21–23</sup>.

Additionally, numerous factors can affect the timing and planning of dialysis in patients with CKD, such as asymptomatic status of advanced CKD, rapid progression of underlying kidney disease, and socioeconomic barriers<sup>21</sup>. Our previous study also demonstrated that not the early referral but the planned dialysis improves both quality of life and depression in newly diagnosed patients with ESKD<sup>15</sup>. However, there is limited information regarding the association between planned dialysis and early mortality after dialysis initiation. This study evaluated the effect of planned dialysis on the survival by period after dialysis of patients undergoing incident dialysis, and compared the effects according to the dialysis modality.

# Results

**Baseline characteristics.** Among 2892 newly initiated dialysis patients, 1280 (44.3%) underwent planned dialysis. The mean age was  $62.5 \pm 14.2$  years, and 1125 patients (38.8%) were men (Table 1). More than 50% of the patients had diabetic nephropathy as the primary renal disease. The proportion of peritoneal dialysis (PD) and early referral rate were higher in the planned dialysis group (PD: 35.2% vs. 25.3%; early referral: 58.0% vs. 53.9%; both P < 0.05). The proportion of patients who received nephrology care twice or more was higher in the planned dialysis group than in the unplanned group (P < 0.001). Among the planned dialysis group, 83.3% of patients initiated hemodialysis (HD) via native vascular access and 16.7% of patients initiated HD via synthetic vascular access. Comorbid conditions were similar in both the groups. The mean estimated glomerular filtration rate (eGFR) and urine volume at dialysis group (P < 0.001). Hemoglobin and albumin levels were higher in the planned dialysis group. Among the socioeconomic status factors, joblessness, married status, and independent ambulation rates were higher in the planned dialysis group than in the unplanned dialysis group.

**Mortality rate.** Overall, 1516 deaths (52.4%) occurred during a mean follow-up of  $71.9 \pm 36.7$  months after initiation of dialysis. On Kaplan–Meier curve analysis, the planned dialysis group showed a better survival rate than the unplanned dialysis group during the entire observation period (log-rank P = 0.013; Fig. 1A). By dialysis modality, the mortality rate was significantly lower in the patients undergoing HD with planned dialysis initiation (Fig. 1B), whereas no difference was found in patients undergoing PD (Fig. 1C). The crude mortality rates in patients with planned PD, unplanned PD, planned HD, and unplanned HD were 35.1%, 36.9%, 41.2%, and 54.5%, respectively. The annual mortality rates for the period after dialysis initiation are shown in Supplementary Table S1. In both the planned and unplanned groups, the mortality rate was higher in the early period after dialysis initiation, which did not satisfy the proportional hazards assumption.

Thus, the effect on mortality was analyzed by dividing the period after dialysis into 1-year intervals (Table 2). The planned dialysis group had a decreased risk of mortality during the first 2 years after dialysis initiation in both crude and adjusted models (1st year: adjusted hazard ratio [aHR] 0.49; 95% confidence interval [CI] 0.35–0.67, P < 0.001; 2nd year: aHR 0.64; 95% CI 0.47–0.88, P = 0.005). Mortality risk did not differ between the planned and unplanned groups 2 years after dialysis (all P values > 0.05).

In the subgroup analysis by dialysis modality, the planned HD group had a decreased risk of mortality during the first 2 years after dialysis initiation in the multivariate Cox regression model (1st year: aHR 0.41; 95% CI 0.27–0.60, P<0.001; 2nd year: aHR 0.61; 95% CI 0.42–0.89, P=0.010) (Table 3). However, the planned PD group showed a mortality risk comparable to that of the unplanned group in all periods.

Differences in infection-related mortality rates are shown in Fig. 2. Among all the patients, the planned dialysis group showed higher survival rates for infection-related deaths (Fig. 2A). The planned dialysis group had better survival for infection-related mortality only in patients undergoing HD, but not in patients undergoing PD (Fig. 2B,C). In the Cox regression model used to analyze annual infection-related mortality, the risk of infection-related death during the 1st year in the planned HD group was lower than that in the unplanned HD group (Supplementary Table S2). Planned dialysis did not cause any differences in cardiovascular mortality in all patients and dialysis subgroups (all P > 0.05).

**Predictors for planned dialysis.** Logistic regression analysis was performed to identify the factors associated with planned dialysis (Table 4). Patients who selected PD and those who were partially dependent for ambulation or could move independently were associated with planned dialysis. Anuric patients whose urine volume was less than 100 mL/day also favored planned dialysis.

#### Discussion

This study demonstrated the beneficial effects of planned dialysis on improving early mortality in patients with new-onset ESKD. The first 2-year mortality improvement was clear in the planned dialysis group, while the effect decreased as the time after dialysis initiation increased. In particular, the survival advantages of planned dialysis were found in patients on HD, but not in patients on PD. This study used a nationwide prospective ESKD cohort and long-term mortality data to strengthen the results. Some patients with CKD may delay dialysis and are reluctant to prepare for it. Considering the high mortality in the early stage of dialysis, nephrologists need to educate and guide patients with CKD to prepare for timely initiation of dialysis.

The early period of CKD to ESKD is the most vulnerable period for patients undergoing incident dialysis<sup>5,6</sup>. Although there are differences among countries, up to 30% mortality has been reported within 1 year of dialysis initiation<sup>2</sup>. Among the various risk factors associated with early mortality, unplanned dialysis has the highest risk of early mortality among incident dialysis patients in the United States<sup>4</sup>. We confirmed that planned dialysis

Age, years62.5 ± 13.262.6 ± 14.70.733Ser, male (%)499 (390)620 (38.8)0.744Body mas index, kg/m²23.1 ± 3.323.9 ± 3.40.540Primary renal disease, n (%)706 (55.2)\$25.5 (5.5)1Jbabetes706 (55.2)\$21 (1.43)1.6Giomerulonephritis159 (1.24)180 (1.2)1.6Others230 (1.74)306 (1.90)1.6Dialysity pe, n (%)\$20 (74.5)407 (25.3)1.6PD450 (35.2)407 (25.3)1.6PD450 (35.2)407 (25.3)1.612 months58 (42.0)742 (86.0)869 (53.9)1.612 months58 (42.0)742 (86.0)60 (35.2)1.612 months109 (85.7)124 (83.3)1.61.612 months109 (85.7)124 (83.3)1.61.613 Corrony arter disease93 (73.3)137 (85.7)0.2114 Corrony arter disease93 (73.3)137 (85.7)0.2115 Diabetes696 (54.4)85 (1.6)5.22.30.95716 mongloin, g/d15.22.35.22.30.95716 mongloin, g/d15.22.40.957
Sex, male n (%)626 (38.9)6.0 (974Body mas index, kg/m²2.0 1 : 1.3.02.0 1 : 3.00.540Primary rend disease, n (%)76 (55.2)895 (55.5)1.0Diabetes760 (55.2)231 (1.4.3)1.0Hypertension159 (12.4)180 (11.2)1.0Glomerulonephritis159 (12.4)306 (19.0)1.0Diabets223 (17.4)306 (19.0)1.0Diabets230 (13.6)1.05 (74.5)1.0PD80 (64.8)1.05 (74.5)1.0PD80 (64.8)1.05 (74.5)1.0PD80 (64.8)1.05 (74.5)1.0S12 months742 (58.0)869 (53.9)1.0> 12 months80 (64.1)1.01.0Number of nephrology clinic visits before dialysis (n = 2764), n (%)1.04 (12.6)1.0158 (4.7)1.94 (13.6)1.01.0220.06 (99.7)1.24 (8.3.3)1.01.058 (4.7)1.04 (13.6)1.01.0221.06 (97.1)1.37 (10.4)1.67 (10.4)22.00.05 (13.6)1.01.01.01.01.07 (10.4)1.02 (10.4)1.02.0Comorbidity, n (%)1.1 (2.9)1.01.02.0Comorbidity index5.2 ± 3.00.0571.01.01.0 (10.4)1.01.01.01.0 (10.4)1.0 (10.4)1.01.01.0 (10.4)1.0 (10.4)1.01.01.0 (10.4
Body mass index, kg/m³23.1 ± 3.323.0 ± 3.40.540Primary renal disease, n (%)706 (55.2)80 (50.0950.09Diabetes706 (55.2)231 (14.3)14.Hypertension195 (15.2)231 (14.3)16.Glomerulonephritis192 (12.4)180 (11.2)6.Others230 (14.3)306 (19.0)1Diabets830 (64.8)1205 (74.5)7.PD400 (52.3)407 (25.3)1PD400 (52.3)7.43 (46.1)1S12 months581 (42.0)7.43 (46.1)1S12 months581 (42.0)7.43 (46.1)1S12 months584 (42.0)7.43 (46.1)1Name of neptrology clinic visits before dialysis (n=2764), n(%)194 (12.6)1221006 (87.7)134 (80.3)11584 (42.0)194 (12.6)11221006 (87.7)134 (80.3)11584 (42.0)194 (12.6)11221006 (87.7)134 (80.3)122100 (13.84 (33.1)1122100 (13.84 (33.1)1122100 (13.94 (33.1)1122100 (13.94 (30.1)1122100 (13.94 (30.1)1122100 (13.94 (30.1)1122100 (13.94 (30.1)112210 (13.94 (30.1)11<
Primary renal disease, n (%)
Dabetes706 (55.2)895 (55.)IHyperension195 (12.0)231 (14.3)IGlomerulonephritis159 (12.4)306 (10.0)IDialysis type, n (%)223 (17.4)306 (10.0)IDialysis type, n (%)830 (64.8)1205 (74.5)IPD450 (35.2)470 (53.0)IIPD512 months407 (53.0)II512 months743 (86.1)869 (33.9)II512 months68 (56.6)64 (4.2)IINumber of neptrology clinic visits before dialysis (n = 2764), n (%)124 (86.3)II2100 (15.2)124 (86.3)IIIComordy attery disease100 (12.6)124 (86.3)II2100 (12.6)124 (86.3)IIIComoray attery disease100 (12.6)124 (86.3)IICoronary attery disease100 (12.7)128 (85.1)0.672II bioletes696 (54.4)87 (55.1)0.621II bioletes994 (16.4)94.140.008II conduce nitrigen, mg/dL52.2352.23III bioletes114 (12.9)90.432.0III bioletes124 (14.1)84.43.184.41.10.008I conduce nitrigen, mg/dL14.14.20.001II conduce nitrigen, mg/dL14.14.20.001II conduce nitrigen, mg/dL14.14.384.41.10.001I co
Hypertension195 (15.2)231 (14.3)1Glomerulonephritis159 (12.4)180 (11.2)1Others223 (17.4)360 (61.9)1Dialysis type, n(%)\$30 (64.8)1205 (74.5)1PD450 (35.2)407 (25.3)7PD450 (35.2)407 (25.3)1PD450 (35.2)407 (25.3)1S12 months742 (58.0)869 (53.9)1> 12 months538 (42.0)743 (46.1)1Number of nephrology clinic visits before dialysis (n =2764), n (%)548 (56.0)64 (4.2)158 (4.7)194 (12.6)121066 (89.7)1284 (83.3)1Comoridities, n (%)100 (89.7)1284 (83.3)0.021Coronary artery disease106 (12.5)202 (12.6)0.903Coronary artery disease93 (7.3)137 (8.5)0.221Diabets696 (54.4)887 (55.1)0.667Congestive heart failure117 (9.1)167 (10.4)0.264Modifie Charlson comorbidity index52 ± 2.352 ± 2.30.901Creating, ng/dL99 1.69.01.7<0.001
Glomerulonephritis159 (12.4)180 (11.2)1Others223 (17.4)306 (19.0)1Dialysis type, n (%)830 (64.8)1205 (74.5)7PD450 (35.2)407 (25.3)7PD450 (35.2)407 (25.3)7PD724 (58.0)869 (53.9)5> 12 months538 (42.0)743 (46.1)7Number of nephrology clinic visits before dialysis (n = 2764), n (%)None68 (5.6)64 (4.2)7111069 (89.7)1248 (8.3)521060 (89.7)1248 (8.3)6620001 (306 (89.7)1248 (8.3)0.667Coronary artery disease93 (7.3)137 (8.5)0.221Diabets696 (54.4)887 (55.1)0.6267Congestive heart failure117 (9.1)167 (10.4)0.264Modified Charlson comorbidity index5.24.2.30.957Hemoglobin, g/dL994.1.69.94.1.7<0.001
Others223 (17.4)306 (19.0)Dialysis type, n (%)<0.001
Dialysis type, n (%)< </td
HD830 (64.8)1205 (74.5)IPD450 (35.2)407 (25.3) $($
PD450 (35.2)407 (25.3)0.029> 12 months742 (58.0)869 (53.9)74≤ 12 months538 (42.0)743 (46.1)74Number of nephrology clinic visits before dialysis (n=2764), n (%)68 (5.6)64 (4.2)74None68 (5.6)64 (4.2)7474158 (4.7)194 (12.6)7474≥ 21096 (89.7)1284 (83.3)7474Comorbidities, n (%)100 (12.5)202 (12.6)0.963Cornory artery disease160 (12.5)137 (8.5)0.221Diabetes696 (54.4)887 (55.1)0.667Congetive heart failure117 (9.1)167 (10.4)0.264Modified Charlson comorbidity index5.24 2.35.24 2.30.957Hemoglobing y'dL9.94 1.69.04 1.7<0.001
Time from referral to dialysis, n (%)       0.029         > 12 months       742 (58.0)       869 (53.9) $\leq$ 12 months       538 (42.0)       743 (46.1)          Number of nephrology clinic visits before dialysis (n=2764), n (%)            None       68 (5.6)       64 (4.2)           1       58 (4.7)       194 (12.6)           2       1096 (89.7)       1284 (83.3)           Comorbidities, n (%)       0001 (100 (12.5)       202 (12.6)       0.963         Cerebrovascular disease       93 (7.3)       137 (8.5)       0.221         Diabetes       696 (54.4)       887 (55.1)       0.667         Congestive heart failure       117 (9.1)       167 (10.4)       0.264         Modified Charlson comorbidity index       52 ± 2.3       52 ± 2.3       0.957         Hemoglobin, g/dL       9.9 ± 1.6       9.0 ± 1.7       <0.001
> 12 months       742 (58.0)       869 (53.9) $\leq$ 12 months       538 (42.0)       743 (46.1)          Number of nephrology clinic visits before dialysis (n = 2764), n (%)       <
$\leq 12 \text{ months}$ $538 (42.0)$ $743 (46.1)$ Number of nephrology clinic visits before dialysis (n = 2764), n (%)         <
Number of nephrology clinic visits before dialysis (n = 2764), n (%)         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <          <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <          <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <         <          Output         I
None         68 (5.6)         64 (4.2)         I           1         58 (4.7)         194 (12.6)         I           2         1096 (89.7)         1284 (83.3)         I           Comorbidities, n (%)         Io0 (12.5)         202 (12.6)         0.963           Cerebrovascular disease         93 (7.3)         137 (8.5)         0.221           Diabetes         696 (54.4)         887 (55.1)         0.667           Congestive heart failure         117 (9.1)         167 (10.4)         0.264           Modified Charlson comorbidity index         5.2 ± 2.3         5.2 ± 2.3         0.957           Hemoglobin, g/dL         9.9 ± 1.6         9.0 ± 1.7         < 0.001
1         58 (4.7)         194 (12.6)         1 $\geq 2$ 1096 (89.7)         1284 (83.3)         I           Comorbidities, n (%) $006 (89.7)$ 1284 (83.3)         I           Coronary artery disease         160 (12.5)         202 (12.6)         0.963           Cerebrovascular disease         93 (7.3)         137 (8.5)         0.221           Diabetes         696 (54.4)         887 (55.1)         0.667           Congestive heart failure         117 (9.1)         167 (10.4)         0.264           Modified Charlson comorbidity index         5.2 ± 2.3         5.2 ± 2.3         0.957           Hemoglobin, g/dL         9.9 ± 1.6         0.9 ± 1.7         <0.001
$\geq 2$ 1096 (89.7)1244 (83.3)IComorbidities, n (%)160 (12.5)202 (12.6)0.963Coronary artery disease93 (7.3)137 (8.5)0.221Diabetes696 (54.4)887 (55.1)0.667Congestive heart failure117 (9.1)167 (10.4)0.264Modified Charlson comorbidity index5.2 $\pm$ 2.35.2 $\pm$ 2.30.957Hemoglobin, g/dL9.9 $\pm$ 1.69.0 $\pm$ 1.7<0.001
Comorbidities, n (%)         I60 (12.5)         202 (12.6)         0.963           Coronary artery disease         93 (7.3)         137 (8.5)         0.221           Diabetes         696 (54.4)         887 (55.1)         0.667           Congestive heart failure         117 (9.1)         167 (10.4)         0.264           Modified Charlson comorbidity index         5.2±2.3         5.2±2.3         0.957           Hemoglobin, g/dL         9.9±1.6         9.0±1.7         <0.001
Coronary artery disease         160 (12.5)         202 (12.6)         0.963           Cerebrovascular disease         93 (7.3)         137 (8.5)         0.221           Diabetes         696 (54.4)         887 (55.1)         0.667           Congestive heart failure         117 (9.1)         167 (10.4)         0.264           Modified Charlson comorbidity index         5.2 $\pm$ 2.3         5.2 $\pm$ 2.3         0.957           Hemoglobin, g/dL         9.9 $\pm$ 1.6         9.0 $\pm$ 1.7         <0.001
Cerebroxacular disease93 (7.3)137 (8.5)0.221Diabetes696 (54.4)887 (55.1)0.667Congestive heart failure117 (9.1)167 (10.4)0.264Modified Charlson comorbidity index5.2±2.35.2±2.30.957Hemoglobin, g/dL9.9±1.69.0±1.7<0.001
Diabetes66 (54.4)887 (55.1)0.667Congestive heart failure117 (9.1)167 (10.4)0.264Modified Charlson comorbidity index $5.2\pm 2.3$ $5.2\pm 2.3$ $0.957$ Hemoglobin, g/dL $9.9\pm 1.6$ $9.0\pm 1.7$ $<0.001$ Blood urea nitrogen, mg/dL $71.1\pm 29.1$ $79.0\pm 39.2$ $<0.001$ Creatinine, mg/dL $71.1\pm 29.1$ $79.0\pm 39.2$ $<0.001$ Creatinine, mg/dL $8.4\pm 3.1$ $8.8\pm 4.1$ $0.008$ eGFR, mL/min/1.73 m² $7.4\pm 3.1$ $7.6\pm 4.2$ $0.059$ Albumin, g/dL $3.6\pm 0.5$ $3.3\pm 0.6$ $<0.001$ Calcium, mg/dL $8.2\pm 1.0$ $7.8\pm 1.0$ $<0.001$ Calcium, mg/dL $5.1\pm 1.6$ $5.5\pm 2.0$ $<0.011$ Urine volume, mL/day $82.1$ $80.7\pm 525.0$ $0.218$ Urine volume, mL/day, n (%) $238$ (18.6) $181$ (11.2) $<0.001$ Work status (n = 2754), n (%) $922$ (76.5) $1134$ (73.2) $=0.048$ Jobless, including students $922$ (76.5) $1134$ (73.2) $=0.435$ Education (n = 2740), n (%) $=0.433$ (36.5) $568$ (36.5) $=0.435$ <9 years
Congestive heart failure117 (9.1)167 (10.4)0.264Modified Charlson comorbidity index $5.2 \pm 2.3$ $5.2 \pm 2.3$ $0.957$ Hemoglobin, g/dL $9.9 \pm 1.6$ $9.0 \pm 1.7$ $<0.001$ Blood urea nitrogen, mg/dL $71.1 \pm 29.1$ $79.0 \pm 39.2$ $<0.001$ Creatinine, mg/dL $8.4 \pm 3.1$ $8.8 \pm 4.1$ $0.008$ eGFR, mL/min/1.73 m <sup>2</sup> $7.4 \pm 3.1$ $7.6 \pm 4.2$ $0.059$ Albumin, g/dL $3.6 \pm 0.5$ $3.3 \pm 0.6$ $<0.001$ Calcium, mg/dL $8.2 \pm 1.0$ $7.8 \pm 1.0$ $<0.001$ Calcium, mg/dL $5.1 \pm 1.6$ $5.5 \pm 2.0$ $<0.001$ Phosphate, mg/dL $5.1 \pm 1.6$ $5.5 \pm 2.0$ $<0.001$ Urine volume, mL/day $781.2 \pm 574.1$ $806.7 \pm 52.5.0$ $<0.001$ Work status (n = 2754), n (%) $238 (18.6)$ $1134 (73.2)$ $<0.001$ Belpoyed $232 (276.5)$ $1134 (73.2)$ $<0.435$ education (n = 2740), n (%) $212 (76.5)$ $1134 (73.2)$ $<0.435$ $< 9$ years $433 (36.5)$ $568 (36.5)$ $<0.001$ $10-12$ years $321 (27.1)$ $391 (25.1)$ $<0.001$ Insurance (n = 2860), n (%) $<0.021$ $<0.021$ $<0.001$ Medical aic covered for poor $370 (29.30)$ $347 (21.73)$ $<0.001$ Medical insurance $89 (370.70)$ $120 (78.27)$ $<0.002$
Modified Charlson comorbidity index5.2 ± 2.35.2 ± 2.30.957Hemoglobin, g/dL9.9 ± 1.69.0 ± 1.7<0.001
Hence Hence location frame and the first stateHence Hence 9.9 ± 1.6Hence Hence 9.9 ± 1.6Hence Hence 9.0 ± 1.7<0.001Blood urea nitrogen, mg/dL71.1 ± 29.179.0 ± 39.2<0.001
Interpreting performInterpreting performInterpreting performInterpreting performBlood urea nitrogen, mg/dL71.1 ± 29.179.0 ± 39.2<0.001
Internet and any graphing and Creatinine, mg/dLInternet (1000)Internet (1000)GFR, mL/min/1.73 m² $7.4 \pm 3.1$ $8.8 \pm 4.1$ $0.008$ eGFR, mL/min/1.73 m² $7.4 \pm 3.1$ $7.6 \pm 4.2$ $0.059$ Albumin, g/dL $3.6 \pm 0.5$ $3.3 \pm 0.6$ $< 0.001$ Calcium, mg/dL $8.2 \pm 1.0$ $7.8 \pm 1.0$ $< 0.001$ Phosphate, mg/dL $5.1 \pm 1.6$ $5.5 \pm 2.0$ $< 0.001$ Urine volume, mL/day $781.2 \pm 574.1$ $806.7 \pm 525.0$ $0.218$ Urine volume < 100 mL/day, n (%)
a final of a gatefinal final fieldfinal fieldeGFR, mL/min/1.73 m²7.4 ± 3.17.6 ± 4.20.059Albumin, g/dL3.6 ± 0.53.3 ± 0.6<0.001
Albumin, g/dLNote and the formAlbumin, g/dL $3.6 \pm 0.5$ $3.3 \pm 0.6$ <0.001
Calcium, ng/dL $8.2 \pm 1.0$ $7.8 \pm 1.0$ $< 0.001$ Phosphate, ng/dL $5.1 \pm 1.6$ $5.5 \pm 2.0$ $< 0.001$ Urine volume, mL/day $781.2 \pm 574.1$ $806.7 \pm 525.0$ $0.218$ Urine volume < 100 mL/day, n (%)
Phosphate, mg/dL       5.1 ± 1.6       5.5 ± 2.0       <0.001
IntegrateInternetInternetInternetInternetUrine volume, mL/day781.2 $\pm$ 574.1806.7 $\pm$ 525.00.218Urine volume < 100 mL/day, n (%)
Vince volume, initial all       100 mL/day, n (%)       238 (18.6)       181 (11.2)       <0.001
Work status (n = 2754), n (%)       200 (100)       101 (112)       0.048         Jobless, including students       922 (76.5)       1134 (73.2)       1000         Employed       283 (23.5)       415 (26.8)       0.435         Education (n = 2740), n (%)       0.435       0.435         < 9 years
Jobiess, including students       922 (76.5)       1134 (73.2)         Employed       283 (23.5)       415 (26.8)         Education (n = 2740), n (%)       0.435         < 9 years
initial products       initial products       initial products       initial products         Employed       283 (23.5)       415 (26.8)       0.435         Education (n = 2740), n (%)       0.435       0.435         <9 years
Education (n = 2740), n (%)       0.435         <9 years
<9 years
10-12 years       431 (36.4)       596 (38.3)         >13 years       321 (27.1)       391 (25.1)         Insurance (n = 2860), n (%)       <
10 12 years     321 (27.1)     391 (25.1)       > 13 years     321 (27.1)     391 (25.1)       Insurance (n = 2860), n (%)     < 0.001
Insurance (n = 2860), n (%)       <0.001
Medical aid covered for poor         370 (29.30)         347 (21.73)           Medical insurance         893 (70.70)         1250 (78.27)
Medical au coverca foi poor         57 (27.00)         517 (21.75)           Medical insurance         893 (70.70)         1250 (78.27)
$\frac{0.002}{1250(10.27)} = 0.002$
(1)
Single/divorced/separated/widowed         259 (21.60)         413 (26.46)
Married         Q40 (78.40)         1148 (73.54)
Ambulation status (n = 2888) n (%)
Independent         1138 (80 1)         1334 (82 0)
Dartially dependent         137 (10.7)         227 (14.1)
Dependent         3/(10./)         22/(14.1)
Experiment         5 (0.2)         47 (3.0)           Family support (n = 2967) n (%)         0.001
ranny support (n - 2007), n (%)         0.091           Name         151 (12.0)         152 (0.5)
NUNC         151 (12.0)         152 (9.5)           Destial         000 (71.2)         1104 (72.0)
ratual         899 (/1.2)         1184 (/3.8)           Full support         212 (16.0)         260 (16.0)
run support 212 (10.8) 209 (10.8)
Sillowing (II – 2627), II (70)         0.695           Name         701 (75.0)
None //01 (50.2) 881 (55.8)

	Planned (n = 1280)	Unplanned (n = 1612)	P value
Current	125 (10.0)	174 (11.0)	
Ex-smoker	421 (33.8)	525 (33.2)	

**Table 1.** Baseline characteristics of the enrolled dialysis patients. *HD* hemodialysis, *PD* peritoneal dialysis,

 *eGFR* estimated glomerular filtration rate.



**Figure 1.** Kaplan–Meier curves for the cumulative risk of death according to planned dialysis. (A) All patients (B) Patients undergoing hemodialysis (C) Patients undergoing peritoneal dialysis. *HD* hemodialysis, *PD* peritoneal dialysis.

				Univariate		Multivariate*	
Time after dialysis, years	Туре	Patient-years	No. of death	HR (95% CI)	P value	aHR (95% CI)	P value
0.1	Unplanned	1519.8	167	Reference		Reference	
0-1	Planned	1257.0	53	0.38 (0.28-0.52)	< 0.001	0.51 (0.37-0.72)	< 0.001
1–2	Unplanned	1381.7	122	Reference		Reference	
	Planned	1193.7	72	0.68 (0.51-0.91)	0.010	0.71 (0.52-0.98)	0.037
2-3	Unplanned	1268.0	108	Reference		Reference	
	Planned	1109.5	95	1.01 (0.76–1.33)	0.969	0.95 (0.69–1.30)	0.739
3-4	Unplanned	1162.6	119	Reference		Reference	
	Planned	1006.5	108	1.05 (0.81-1.36)	0.720	1.02 (0.77-1.37)	0.873
4–5	Unplanned	1046.2	105	Reference		Reference	
	Planned	907.7	83	0.91 (0.68–1.22)	0.527	0.77 (056–1.06)	0.109
. 5	Unplanned	926.7	244	Reference		Reference	
25	Planned	812.7	240	1.02 (0.87-1.22)	0.810	1.00 (0.82–1.23)	0.969

**Table 2.** Hazard ratios for annual mortality of planned dialysis by Cox proportional hazard model. \*Adjusted for age, sex, mCCI, serum hemoglobin, albumin, calcium, phosphate, 24-h urine volume, work status, insurance, marital status, and ambulation status. *HR* hazard ratio, *CI* confidence interval, *aHR* adjusted hazard ratio, *mCCI* modified Charlson comorbidity index.

.

could effectively improve early mortality by analyzing annual mortality after dialysis initiation. Therefore, it is necessary to actively initiate planned dialysis. It can be difficult to persuade patients to undergo planned dialysis. Complex determinants of planned dialysis include different patient characteristics, medical costs for preparing dialysis, adherence to care, and underlying conditions<sup>6</sup>. Despite these complexities, nephrologists need to fully explain the advantages and provide patients with the opportunity for planned dialysis.

Globally, medical expenses for treating patients with ESKD have been increasing<sup>24</sup>. It has been confirmed that planned dialysis has the advantage of reducing medical costs and mortality. Shimizu et al. analyzed the 2-year mortality and medical costs of patients undergoing incident dialysis in Japan<sup>25</sup>. After adjusting for various confounding factors, planned dialysis was associated with lower mortality and medical costs. Although the health insurance system differs among countries, Japan has compulsory affiliation, free access, and a low copayment

Time after		Hemodialysis				Peritoneal dialysis			
dialysis, years	Туре	Patient- years	No. of death	aHR* (95% CI)	P value	Patient- years	No. of death	aHR* (95% CI)	P value
0-1	Unplanned	1119.6	149	Reference		400.1	18	Reference	
	Planned	815.5	32	0.41 (0.27–0.62)	< 0.001	441.5	21	1.15 (0.59–2.27)	0.679
	Unplanned	1007.3	94	Reference		374.5	28	Reference	
1-2	Planned	776.7	45	0.66 (0.44-0.99)	0.045	416.9	27	0.78 (0.44-1.38)	0.393
2-3	Unplanned	925.0	74	Reference		343.0	34	Reference	
	Planned	721.4	64	0.96 (0.64–1.44)	0.849	388.1	31	0.79 (0.47-1.34)	0.384
3-4	Unplanned	853.7	79	Reference		308.9	40	Reference	
	Planned	653.5	70	1.24 (0.86–1.80)	0.248	353.0	38	0.74 (0.46-1.21)	0.229
4-5	Unplanned	770.3	81	Reference		275.9	24	Reference	
	Planned	594.7	48	0.58 (0.38–0.88)	0.010	313.1	35	1.11 (0.63–1.98)	0.715
> 5	Unplanned	683.2	180	Reference		243.5	64	Reference	
	Planned	538.2	173	1.08 (0.85-1.38)	0.535	274.5	67	0.79 (0.54-1.15)	0.221

**Table 3.** Hazard ratios for annual mortality of planned dialysis by Cox proportional hazard model in hemodialysis and peritoneal dialysis. \*Adjusted for age, sex, mCCI, serum hemoglobin, albumin, calcium, phosphate, 24-h urine volume, work status, insurance, marital status, and ambulation status. *aHR* adjusted hazard ratio, *CI* confidence interval, *mCCI* modified Charlson comorbidity index.





health insurance system, similar to South Korea<sup>26</sup>. Therefore, planned dialysis would benefit the financial stability of the long-term national healthcare system in South Korea.

Early referral to nephrologists has several benefits for patients with CKD, such as treating reversible causes of nephropathy, specialized nephrology management, and the optimal time to educate and prepare renal replacement therapy<sup>17</sup>. However, in our previous study, the advantages for mortality or quality of life could not be confirmed in early referral patients, including both planned and unplanned dialysis<sup>15,27</sup>. This may be related to the proportion of planned dialysis among the early referral patients. Our results revealed that early referral was not associated with planned dialysis, despite sufficient time. This indicates that preparation of the dialysis approach and optimal dialysis initiation are more important factors in improving mortality than early referral itself. In addition, more than half of the patients with early referral still did not receive planned dialysis, which indicates that there will be a blind spot where we need to pay attention.

Among HD and PD, patients with planned HD showed an improvement in mortality in the early period of dialysis compared to those with unplanned HD. This might be related to the increased risk of infection, such as catheter-related infections, in patients undergoing unplanned HD. The results of the subgroup analysis that showed increased infection-related mortality during the 1st year after HD support the probability of causation.

	Univariate		Multivariate						
Variables	OR (95% CI)	P value	aOR (95% CI)	P value					
Age	1.00 (0.99–1.00)	0.423	1.01 (1.00-1.01)	0.122					
Sex	1.00 (0.86–1.17)	0.968	1.00 (0.86–1.17)	0.984					
Early referral									
≤12 months	Reference		Reference						
>12 months	1.18 (1.02–1.37)	0.029	1.16 (0.99–1.34)	0.063					
Work status									
Jobless including students	Reference								
Employed	0.84 (0.71-1.00)	0.051							
Dialysis type									
HD	Reference		Reference						
PD	1.61 (1.37–1.89)	< 0.001	1.61 (1.36–1.90)	< 0.001					
Ambulation status									
Dependent	Reference		Reference						
Independent	13.90 (0.42-44.70)	< 0.001	12.57 (3.89-40.59)	< 0.001					
Partially dependent	9.78 (2.99-31.98)	0.002	8.95 (2.73-29.34)	0.004					
Urine volume									
<100 mL/day	Reference		Reference						
≥100 mL/day	0.57 (0.46-0.71)	< 0.001	0.55 (0.44-0.68)	< 0.001					

**Table 4.** Factors associated with planned dialysis by logistic regression model. *OR* odds ratio, *CI* confidence interval, *aOR* adjusted odds ratio, *HD* hemodialysis, *PD* peritoneal dialysis.

.....

Previous studies have also confirmed that HD through a temporary catheter increases the risk of infection and thrombosis<sup>28,29</sup>. Yap et al. reported that the prolonged duration of catheter insertion increases the risk of catheter-related bloodstream infection (CRBSI)<sup>30</sup> and the mean duration from catheter insertion to first CRBSI was 6 months. Another study showed the incidence of CRBSI decreases after 9 months after catheter insertion, because of switching to HD using a vascular access. For these reasons, planned HD has an early survival benefit compared to unplanned HD, but the benefit is disappeared later. In addition, patients on PD generally have a lower infectious complication incidence than patients with HD<sup>31</sup>, which may affect the results that there was no difference in early mortality rate between the planned and unplanned PD groups. Therefore, education on the advantages of planned dialysis and preparation of permanent vascular access should be encouraged especially in patients willing to undergo HD.

The factors that hinder optimal initiation of dialysis include patients' reluctance, sudden progression of kidney disease, vascular surgeons' delay in performing vascular access, and physicians' underestimation of CKD status<sup>21,32,33</sup>. Additionally, our results show that patients with CKD with better physical conditions are more likely to select planned dialysis. These patients can tolerate treatment with dialysis preparation and have a longer life expectancy. In addition, patients planning to undergo PD are more likely to select planned dialysis. This may be related to a better understanding of the necessity and options of renal replacement therapy in patients with CKD who are planning PD. In contrast, patients with CKD with a large residual urine volume tend to be reluctant to undergo planned dialysis. In these cases, patients with CKD and clinicians might decide that dialysis was not urgently needed because the symptoms of edema and uremia were not severe. A multidisciplinary approach and government support are needed to overcome these barriers and increase planned dialysis rates. A comprehensive counseling system, including dietary information, psychosocial care, economic support for medical expenses, and education on renal replacement therapy, will help increase the planned dialysis rate<sup>15</sup>. Interestingly, a Taiwanese research group emphasized that incentive reimbursement for healthcare providers at the government level can provide survival benefits and long-term medical cost saving for patients with CKD<sup>34</sup>. To improve the prognosis of patients with CKD, it is important to encourage early regular visits to a nephrologist and long-term care before dialysis<sup>35,36</sup>. Incentives for nephrology care will be helpful to increase the opportunity for early referral and professional care in this respect. As part of this effort, the Korean Society of Nephrology recently introduced a shared decision-making (SDM) program<sup>37,38</sup>. SDM can help improve patients' knowledge of renal replacement therapy and reduce unnecessary conflicts in the decision-making process related to uncertainty regarding their worth<sup>37</sup>. These programs will contribute to increasing the planned dialysis rate and improving patient outcomes.

The strength of this study was that we identified the long-term mortality of dialysis patients and determined how long the advantages of planned dialysis were maintained, especially by the dialysis modality. This study had some limitations. First, this was an observational study; therefore, bias could exist between measured and unmeasured confounders. However, it is impossible to perform a randomized controlled trial on this subject owing to ethical issues. We used a nationwide ESKD cohort with a relatively large number of patients and adjusted for various possible confounding factors to reduce the bias. Second, we could not specify the reason or pathophysiological mechanism to explain the improvement in mortality from planned dialysis. Third, there may be some limitations for generalizing the study results due to Korea's unique care system and racial characteristics. Forth, we could not investigate the effect of planned dialysis on HD or PD technical survival other than patient survival. This needs to be confirmed with future research.

In conclusion, planned dialysis has survival benefits over unplanned dialysis during the early dialysis period. The beneficial effects lasted up to 2 years after the initiation of dialysis. The advantages of planned dialysis were evident in patients undergoing HD. Optimal dialysis initiation should be recommended as a multidisciplinary approach to reduce early mortality in patients undergoing incident dialysis.

#### Methods

**Study population.** This study analyzed patient data from the Clinical Research Center for End-Stage Renal Disease (CRC for ESRD) in Korea. The CRC for ESRD cohort is a nationwide, multicenter, web-based, prospective cohort of patients with ESKD undergoing dialysis in 31 hospitals in South Korea (NCT00931970). The details of the study cohort have been previously described<sup>39</sup>. Between July 2009 and June 2015, a total of 2892 patients aged > 20 years and newly diagnosed with ESKD who underwent maintenance dialysis for 3 months were enrolled and analyzed (Fig. 3). The medical ethics committees of all participating dialysis centers approved the CRC registry for ESRD, and informed consent was obtained from all patients before inclusion.

**Data collection.** All cohort data were registered in the web-based CRC for ESRD database, and data related to this study were selectively extracted. Baseline patient information, including age, sex, height, weight, body mass index, primary renal disease, dialysis type, comorbid diseases, modified Charlson comorbidity index (mCCI), and laboratory data, was collected at enrollment. The mCCI was calculated for each patient at initiation of dialysis<sup>40,41</sup>, and the eGFR was calculated using the CKD-Epidemiology Collaboration equation<sup>42,43</sup>. Patient information associated with socioeconomic status, including work status, education, ambulation status, and family support, was also collected at enrollment. Planned dialysis was defined as dialysis therapy initiated with permanent access to and maintenance of the initial dialysis modality for at least 90 days. Dialysis modality was defined as the modality maintained 90 days after dialysis initiation or at dialysis initiation if death occurred within 90 days.



Figure 3. Study population. ESKD end-stage kidney disease, HD hemodialysis, PD peritoneal dialysis.

Scientific Reports | (2023) 13:6049 | http

**Outcomes.** The main outcome was all-cause mortality after dialysis initiation. Mortality data, including the cause of death in cohort patients up to December 2019 were obtained from Statistics Korea, and patients were censored at the time of kidney transplantation. Analyses according to the cause of death and dialysis modality were also performed.

**Statistical analysis.** Continuous variables were presented as mean±standard deviation, and categorical variables were presented as numbers and percentages. Student's t-test was used to compare continuous variables between the planned and unplanned dialysis groups, and Pearson's chi-square test or Fisher's exact test was used to compare distributions of categorical variables between groups, as appropriate. Kaplan–Meier curves and log-rank test were used to compare the differences in mortality between the planned and unplanned dialysis groups. The association between planned dialysis and mortality according to time after dialysis was determined using multivariable Cox proportional hazard regression models. Adjustment factors were selected as clinically relevant variables, including age, sex, mCCI, 24-h urine volume, work status, insurance, marital status, and ambulation status. The proportional hazards assumption was tested using graphical and weighted residual analyses. Weighted residual analyses demonstrated that the proportional hazards assumption was violated, and we fitted separate models for annual intervals. Factors associated with planned dialysis were evaluated using a logistic regression analysis. Factors that differed in their baseline characteristics were selected in the univariable analysis. Variables with significance, including age and sex, were included in the multivariate analysis. Statistical analyses were performed using SPSS version 22.0 (IBM Corp., Armonk, NY, USA) and R (R Foundation for Statistical Computing, Vienna, Austria; www.r-project.org). *P* values < 0.05 were considered statistically significant.

**Ethics declarations.** The data do not contain personal information and do not infringe on the privacy of patients. This study was approved by the Institutional Review Board of the Kyungpook National University Hospital (2011-01-041). All patients provided written informed consent before participation, and the study was conducted according to the tenets of the 2013 Declaration of Helsinki.

# Data availability

The data that support the findings of this study are available on reasonable request from the corresponding authors. The data are not publicly available due to privacy or ethical restriction.

Received: 7 December 2022; Accepted: 9 April 2023 Published online: 13 April 2023

#### References

- Hong, Y. A. et al. Trends in epidemiologic characteristics of end-stage renal disease from 2019 Korean Renal Data System (KORDS). Kidney Res. Clin. Pract. 40, 52–61. https://doi.org/10.23876/j.krcp.20.202 (2021).
- 2. Zhou, H. *et al.* Early mortality among peritoneal dialysis and hemodialysis patients who transitioned with an optimal outpatient start. *Kidney Int. Rep.* **4**, 275–284. https://doi.org/10.1016/j.ekir.2018.10.008 (2019).
- Saran, R. et al. US renal data system 2016 annual data report: Epidemiology of kidney disease in the United States. Am. J. Kidney Dis. 69, A7-a8. https://doi.org/10.1053/j.ajkd.2016.12.004 (2017).
- Foley, R. N., Chen, S. C., Solid, C. A., Gilbertson, D. T. & Collins, A. J. Early mortality in patients starting dialysis appears to go unregistered. *Kidney Int.* 86, 392–398. https://doi.org/10.1038/ki.2014.15 (2014).
- Chan, K. E. et al. Early outcomes among those initiating chronic dialysis in the United States. Clin. J. Am. Soc. Nephrol. 6, 2642–2649. https://doi.org/10.2215/cjn.03680411 (2011).
- Robinson, B. M. et al. Worldwide, mortality risk is high soon after initiation of hemodialysis. Kidney Int. 85, 158–165. https://doi. org/10.1038/ki.2013.252 (2014).
- Bradbury, B. D. *et al.* Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Clin. J. Am. Soc. Nephrol.* 2, 89–99. https://doi.org/10.2215/cjn.01170905 (2007).
- Cooper, B. A., Penne, E. L., Bartlett, L. H. & Pollock, C. A. Protein malnutrition and hypoalbuminemia as predictors of vascular events and mortality in ESRD. Am. J. Kidney Dis. 43, 61–66. https://doi.org/10.1053/j.ajkd.2003.08.045 (2004).
- Pisoni, R. L. et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis. 44, 94–111. https://doi.org/10.1053/j.ajkd.2004.03.023 (2004).
- Herzog, C. A. et al. Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. Kidney Int. 68, 818–825. https://doi.org/10.1111/j.1523-1755.2005.00462.x (2005).
- Kim, D. H. et al. Effects of the route of erythropoietin administration on hemoglobin variability and cardiovascular events in hemodialysis patients. *Kidney Res. Clin. Pract.* 40, 724–733. https://doi.org/10.23876/j.krcp.20.260 (2021).
- 12. Arora, P. *et al.* Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center. *J. Am. Soc. Nephrol.* **10**, 1281–1286. https://doi.org/10.1681/asn.V1061281 (1999).
- Kessler, M., Frimat, L., Panescu, V. & Briançon, S. Impact of nephrology referral on early and midterm outcomes in ESRD: Epidémiologie de l'Insuffisance REnale chronique terminale en Lorraine (EPIREL): Results of a 2-year, prospective, community-based study. Am. J. Kidney Dis. 42, 474–485. https://doi.org/10.1016/s0272-6386(03)00805-9 (2003).
- Lin, C. L., Chuang, F. R., Wu, C. F. & Yang, C. T. Early referral as an independent predictor of clinical outcome in end-stage renal disease on hemodialysis and continuous ambulatory peritoneal dialysis. *Ren. Fail.* 26, 531–537. https://doi.org/10.1081/jdi-20003 1733 (2004).
- Park, J. I. *et al.* Not early referral but planned dialysis improves quality of life and depression in newly diagnosed end stage renal disease patients: A prospective cohort study in Korea. *PLoS ONE* 10, e0117582. https://doi.org/10.1371/journal.pone.0117582 (2015).
- Lee, J. et al. Early nephrology referral reduces the economic costs among patients who start renal replacement therapy: A prospective cohort study in Korea. PLoS ONE 9, e99460. https://doi.org/10.1371/journal.pone.0099460 (2014).
- 17. Kim, D. H. *et al.* Early referral to a nephrologist improved patient survival: Prospective cohort study for end-stage renal disease in Korea. *PLoS ONE* **8**, e55323. https://doi.org/10.1371/journal.pone.0055323 (2013).
- Chan, M. R., Dall, A. T., Fletcher, K. E., Lu, N. & Trivedi, H. Outcomes in patients with chronic kidney disease referred late to nephrologists: A meta-analysis. Am. J. Med. 120, 1063–1070. https://doi.org/10.1016/j.amjmed.2007.04.024 (2007).

- Baek, S. H. *et al.* Outcomes of predialysis nephrology care in elderly patients beginning to undergo dialysis. *PLoS ONE* 10, e0128715. https://doi.org/10.1371/journal.pone.0128715 (2015).
- Lee, J. et al. Factors affecting the referral time to nephrologists in patients with chronic kidney disease: A prospective cohort Study in Korea. Medicine 95, e3648. https://doi.org/10.1097/md.00000000003648 (2016).
- Marrón, B. *et al.* Impact of end-stage renal disease care in planned dialysis start and type of renal replacement therapy-a Spanish multicentre experience. *Nephrol. Dial. Transpl.* 21 Suppl 2, ii51-55. https://doi.org/10.1093/ndt/gf191 (2006).
- 22. Lysaght, M. J. Maintenance dialysis population dynamics: Current trends and long-term implications. J. Am. Soc. Nephrol. 13(Suppl 1), S37-40 (2002).
- Lameire, N., Wauters, J. P., Teruel, J. L., Van Biesen, W. & Vanholder, R. An update on the referral pattern of patients with end-stage renal disease. *Kidney Int. Suppl.* https://doi.org/10.1046/j.1523-1755.61.s80.6.x (2002).
- Karopadi, A. N., Mason, G., Rettore, E. & Ronco, C. Cost of peritoneal dialysis and haemodialysis across the world. Nephrol. Dial. Transpl. 28, 2553–2569. https://doi.org/10.1093/ndt/gft214 (2013).
- Shimizu, Y. et al. Emergent initiation of dialysis is related to an increase in both mortality and medical costs. Sci. Rep. 10, 19638. https://doi.org/10.1038/s41598-020-76765-0 (2020).
- Ii, M. & Niu, B. Are Japanese people satisfied with their health care system and services? Empirical evidence from survey data. *Health Policy* 123, 345–352. https://doi.org/10.1016/j.healthpol.2018.11.008 (2019).
- Mendelssohn, D. C. *et al.* Suboptimal initiation of dialysis with and without early referral to a nephrologist. *Nephrol. Dial. Transpl.* 26, 2959–2965. https://doi.org/10.1093/ndt/gfq843 (2011).
- Lok, C. E. & Mokrzycki, M. H. Prevention and management of catheter-related infection in hemodialysis patients. *Kidney Int.* 79, 587–598. https://doi.org/10.1038/ki.2010.471 (2011).
- Thomson, P., Stirling, C., Traynor, J., Morris, S. & Mactier, R. A prospective observational study of catheter-related bacteraemia and thrombosis in a haemodialysis cohort: Univariate and multivariate analyses of risk association. *Nephrol. Dial. Transpl.* 25, 1596–1604. https://doi.org/10.1093/ndt/gfp667 (2010).
- Yap, H. Y. et al. Catheter-related complications and survival among incident hemodialysis patients in Singapore. J. Vasc. Access 19, 602–608. https://doi.org/10.1177/1129729818765055 (2018).
- Aslam, N., Bernardini, J., Fried, L., Burr, R. & Piraino, B. Comparison of infectious complications between incident hemodialysis and peritoneal dialysis patients. *Clin. J. Am. Soc. Nephrol.* 1, 1226–1233. https://doi.org/10.2215/cjn.01230406 (2006).
- Hughes, S. A., Mendelssohn, J. G., Tobe, S. W., McFarlane, P. A. & Mendelssohn, D. C. Factors associated with suboptimal initiation of dialysis despite early nephrologist referral. *Nephrol. Dial. Transpl.* 28, 392–397. https://doi.org/10.1093/ndt/gfs431 (2013).
- Marrón, B. et al. Analysis of patient flow into dialysis: Role of education in choice of dialysis modality. Perit. Dial. Int. 25(Suppl 3), S56-59 (2005).
- Lin, M. Y. et al. Effect of national pre-ESRD care program on expenditures and mortality in incident dialysis patients: A populationbased study. PLoS ONE 13, e0198387. https://doi.org/10.1371/journal.pone.0198387 (2018).
- Lin, M. Y. et al. Effects of physician's specialty on regular chronic kidney disease care in predialysis: A population-based crosssectional study. *Medicine* 97, e11317. https://doi.org/10.1097/md.000000000011317 (2018).
- Chung, C. Y., Wu, P. H., Chiu, Y. W., Hwang, S. J. & Lin, M. Y. Effect of nephrology care on mortality in incident dialysis patients: A population-based cohort study. J. Pers. Med. https://doi.org/10.3390/jpm1111071 (2021).
- Yu, B. C. et al. Effect of shared decision-making education on physicians' perceptions and practices of end-of-life care in Korea. Kidney Res. Clin. Pract. 41, 242–252. https://doi.org/10.23876/j.krcp.21.071 (2022).
- Kim, S. *et al.* Evaluating a shared decision-making intervention regarding dialysis modality: Development and validation of selfassessment items for patients with chronic kidney disease. *Kidney Res. Clin. Pract.* 41, 175–187. https://doi.org/10.23876/j.krcp. 21.125 (2022).
- Lee, J. E. et al. Low serum phosphate as an independent predictor of increased infection-related mortality in dialysis patients: A
  prospective multicenter cohort study. PLoS ONE 12, e0185853. https://doi.org/10.1371/journal.pone.0185853 (2017).
- Chae, J. W. et al. Prediction of mortality in patients undergoing maintenance hemodialysis by Charlson Comorbidity Index using ICD-10 database. Nephron. Clin. Pract. 117, c379-384. https://doi.org/10.1159/000321525 (2011).
- Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J. Chronic Dis. 40, 373–383. https://doi.org/10.1016/0021-9681(87)90171-8 (1987).
- Stevens, L. A. *et al.* Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m<sup>2</sup>. *Am. J. Kidney Dis.* 56, 486–495. https://doi.org/10.1053/j.ajkd.2010.03.026 (2010).
- Levey, A. S. & Stevens, L. A. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: More accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. *Am. J. Kidney Dis.* 55, 622–627. https://doi. org/10.1053/j.ajkd.2010.02.337 (2010).

# Acknowledgements

We express our gratitude to all the study participants.

#### **Author contributions**

Research idea and study design: J.H.L., J.H.K., Y.L.K., J.H.C.; data acquisition: J.H.L., Y.S.K., S.W.K., C.W.Y., N.H.K., H.Y.J., J.Y.C., S.H.P., C.D.K., Y.L.K., J.H.C.; data analysis/interpretation: J.H.L., Y.J., J.H.C.; wrote the paper: J.H.L., J.H.K., Y.L.K., J.H.C.; supervision or mentorship: Y.L.K., J.H.C. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

# Funding

This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI15C0001, HR22C1832), and by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2020R111A3068253, 2021R111A3059702, 2021R111A3047973). This research was supported by a grant of Patient-Centered Clinical Research Coordinating Center (PACEN) funded by the Ministry of Health & Welfare, Republic of Korea (HI19C0481, HC20C0054).

# Competing interests

The authors declare no competing interests.

# Additional information

**Supplementary Information** The online version contains supplementary material available at https://doi.org/ 10.1038/s41598-023-33216-w.

Correspondence and requests for materials should be addressed to Y.-L.K. or J.-H.C.

Reprints and permissions information is available at www.nature.com/reprints.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2023